AVROBIO (AVRO) Q4 2024 earnings summary

Executive summary

• Transitioned to a public company in 2024 and reported positive interim results from TX45 Phase 1b trial in PH-HFpEF patients, supporting ongoing Phase 2 APEX trial endpoints and population.

• Enrolled first subject in TX45 Phase 1b Part B trial for HFrEF in March 2025; topline results expected 2H 2025.

• Completed $185M private placement in February 2025, extending cash runway into Q4 2028.

Financial highlights

• Cash and cash equivalents were $141.2M as of December 31, 2024, down from $159.1M at September 30, 2024.

• Research and development expenses rose to $9.2M in Q4 2024 from $7.1M in Q4 2023, mainly due to increased clinical and manufacturing activities.

• General and administrative expenses increased to $4.8M in Q4 2024 from $2.3M in Q4 2023, reflecting higher costs as a public company.

• Net loss for Q4 2024 was $12.4M, compared to $7.9M in Q4 2023; full-year net loss was $58.0M versus $42.8M in 2023.

Outlook and guidance

• Cash position, including proceeds from the private placement, expected to fund operations through key TX45 Phase 1b/2 readouts and TX2100 clinical development into Q4 2028.

• TX45 Phase 1b Part B topline results anticipated in 2H 2025; APEX Phase 2 topline results expected in 2026.

• TX2100 Phase 1 trial for HHT planned to initiate in Q4 2025 or Q1 2026, pending completion of IND-enabling studies.